203 related articles for article (PubMed ID: 27267694)
41. Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.
Mariotti S; Barbesino G; Caturegli P; Marinò M; Manetti L; Fugazzola L; Pacini F; Pinchera A
J Endocrinol Invest; 1994 Dec; 17(11):861-7. PubMed ID: 7745234
[TBL] [Abstract][Full Text] [Related]
42. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
43. Low level of serum HDL-cholesterol with increased sIL-2R predicts a poor clinical outcome for patients with malignant lymphoma and adult T-cell leukemia-lymphoma.
Komiya I; Tomoyose T; Ouchi G; Yara T; Higa S
Cytokine; 2018 May; 105():57-62. PubMed ID: 29459344
[TBL] [Abstract][Full Text] [Related]
44. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma.
Kumagai S; Tashima M; Fujikawa J; Iwasaki M; Iwamoto Y; Sueki Y; Fukunaga A; Yanagita S; Nishikori M; Takaori-Kondo A; Arima N
Int J Hematol; 2014 Jun; 99(6):737-42. PubMed ID: 24756873
[TBL] [Abstract][Full Text] [Related]
45. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.
Eurelings LEM; Miedema JR; Dalm VASH; van Daele PLA; van Hagen PM; van Laar JAM; Dik WA
PLoS One; 2019; 14(10):e0223897. PubMed ID: 31622413
[TBL] [Abstract][Full Text] [Related]
46. Soluble interleukin-2 receptors in patients with nasopharyngeal carcinoma.
Lai KN; Ho S; Leung JC; Tsao SY
Cancer; 1991 Apr; 67(8):2180-5. PubMed ID: 1848475
[TBL] [Abstract][Full Text] [Related]
47. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Nukui A; Masuda A; Abe H; Arai K; Yoshida KI; Kamai T
BMC Cancer; 2017 May; 17(1):372. PubMed ID: 28545581
[TBL] [Abstract][Full Text] [Related]
48. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma.
Boyano MD; Garcia-Vázquez MD; López-Michelena T; Gardeazabal J; Bilbao J; Cañavate ML; Galdeano AG; Izu R; Díaz-Ramón L; Raton JA; Díaz-Pérez JL
Br J Cancer; 2000 Oct; 83(7):847-52. PubMed ID: 10970683
[TBL] [Abstract][Full Text] [Related]
49. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
50. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
[TBL] [Abstract][Full Text] [Related]
51. The significance of soluble interleukin-2 receptor in monitoring disease relapse in patients with nasopharyngeal cancer.
Wu LJ; Chen KY; Chi KH; Chen SY; Liang MJ; Shiau CY; Wang LW; Liu YM; Chow KC; Yen SH
Jpn J Clin Oncol; 1998 Dec; 28(12):729-32. PubMed ID: 9879289
[TBL] [Abstract][Full Text] [Related]
52. Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.
van den Brand M; van der Velden WJ; Diets IJ; Ector GI; de Haan AF; Stevens WB; Hebeda KM; Groenen PJ; van Krieken HJ
Leuk Lymphoma; 2016 Jul; 57(7):1649-56. PubMed ID: 26694256
[TBL] [Abstract][Full Text] [Related]
53. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
54. Relationship between levels of serum gastric inhibitory polypeptide (GIP), soluble interleukin-2 receptor (sIL-2R), and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and disease condition and prognosis of patients with severe acute pancreatitis.
Zeng L; Xi F; Yang Y; Guo L; Hu H; Yang Q; Ma Q
Ann Palliat Med; 2021 Jun; 10(6):6786-6792. PubMed ID: 34154356
[TBL] [Abstract][Full Text] [Related]
55. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement.
Thi Hong Nguyen C; Kambe N; Kishimoto I; Ueda-Hayakawa I; Okamoto H
J Dermatol; 2017 Jul; 44(7):789-797. PubMed ID: 28295528
[TBL] [Abstract][Full Text] [Related]
56. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
[TBL] [Abstract][Full Text] [Related]
57. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
58. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma.
Vuoristo MS; Laine S; Huhtala H; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E; Kellokumpu-Lehtinen P
Eur J Cancer; 2001 Sep; 37(13):1629-34. PubMed ID: 11527688
[TBL] [Abstract][Full Text] [Related]
59. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
[TBL] [Abstract][Full Text] [Related]
60. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
